{"id":"NCT02842866","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older","officialTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-15","primaryCompletion":"2017-02-13","completion":"2017-02-13","firstPosted":"2016-07-25","resultsPosted":"2020-02-18","lastUpdate":"2022-04-05"},"enrollment":907,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":["MenACYW conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined","otherNames":["Menomune® - A/C/Y/W-135"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Menomune® Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study was to demonstrate non-inferiority of immunogenicity and evaluate the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid conjugate vaccine (MenACYW conjugate vaccine) compared to a single dose of Meningococcal Polysaccharide Vaccine Serogroups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in adults 56 years of age and older in the United States.\n\nPrimary objective:\n\n-To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared to those observed following the administration of a single dose of Menomune® - A/C/Y/W-135.\n\nSecondary objective:\n\n-To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate vaccine to those observed following the administration of Menomune® - A/C/Y/W-135.\n\nObservational objectives:\n\n* To describe antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA at baseline (before vaccination) and 30 days after vaccination with MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 in a subset of 100 participants per treatment group.\n* To describe the safety profile of MenACYW conjugate vaccine compared to that of the licensed Menomune® - A/C/Y/W-135 after a single administration.","primaryOutcome":{"measure":"Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine","timeFrame":"Day 30 (Post-vaccination)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine","deltaMin":58.2,"sd":null},{"arm":"Group 2: Menomune® Vaccine","deltaMin":42.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"56 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":19},"locations":{"siteCount":36,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["32387012"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":448},"commonTop":["Myalgia","Injection Site Pain","Headache","Malaise","Injection Site Erythema"]}}